Use of Recombinant Human Activated Protein C in Toxic Shock Syndrome
Author Information
Author(s): Nasa Prashant, Sehrawat Deepak, Chawla Sudha, Rajesh
Primary Institution: Indraprastha Apollo Hospital, New Delhi, India
Hypothesis
Can recombinant human activated protein C (rhAPC) improve outcomes in patients with nonmenstrual toxic shock syndrome?
Conclusion
The use of rhAPC led to significant improvement in the patient's condition and organ function in the context of toxic shock syndrome.
Supporting Evidence
- The patient's APACHE II score improved from 28 to 8 after treatment with rhAPC.
- Organ failure scores decreased significantly during the treatment period.
- The patient was extubated and transferred out of ICU within a week of starting rhAPC.
Takeaway
A patient with a severe infection called toxic shock syndrome got better after receiving a special medicine that helps the body fight the infection.
Methodology
The patient was treated with a 96-hour infusion of rhAPC after showing signs of worsening multiorgan failure.
Limitations
This is a single case report, limiting the generalizability of the findings.
Participant Demographics
A 27-year-old male with no significant past history.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website